If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
2,922.00    -56.00 (-1.88%)
Bid:
2,919.00
Ask:
2,922.00
Spread: 3.00 (0.103%)
Market Cap: £4.07b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Completed divestment

1 Jul 2022 07:00

RNS Number : 9187Q
Croda International PLC
01 July 2022
 

Stock market announcement

1 July 2022

Completed divestment - transitioning to a pure-play Consumer Care and Life Sciences company

Croda International Plc ('Croda'), which uses smart science to create high performance ingredients and technologies that improve lives, today announces the completion of the divestment of the majority of its Performance Technologies and Industrial Chemicals businesses to a wholly owned subsidiary of Cargill Inc ('Cargill'), as more fully described in Croda's initial announcement on 22 December 2021.

The gross proceeds will be approximately €775m (approximately £667m), subject to small, customary adjustments for cash and debt-like instruments, and working capital, in line with the earlier announcement. The divestment and the associated proceeds exclude Croda Sipo ('Sipo'), a Chinese joint venture in which Croda has a 65% shareholding. Croda continues to discuss with its joint venture partner the acquisition of its stake in Sipo, to enable a subsequent sale by Croda to Cargill of 100% of Sipo for €140m. 

Steve Foots, Chief Executive of Croda, said: "This divestment accelerates Croda's transition to being a pure-play Consumer Care and Life Sciences company. We will redeploy capital and resources to scale our consumer, health and crop care technologies, helping to deliver consistent, superior sales growth and even stronger profit margins."

 

Further information

For enquiries contact:

Investors: David Bishop, Croda +44 7823 874428

Press: Charlie Armitstead, Teneo +44 7703 330269

 

Advisers to Croda

 

Morgan Stanley & Co. International Plc (Financial Adviser & Corporate Broker)

Shirav Patel, Andrew Foster

Centerview Partners (Financial Adviser)

James Hartop

Freshfields Bruckhaus Deringer (Legal Adviser)

Oliver Lazenby

Teneo (Financial PR)

Charlie Armitstead

 

Disclaimers

 

Morgan Stanley & Co. International plc ("Morgan Stanley") which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority and the PRA in the UK is acting exclusively as financial adviser and corporate broker to Croda and no one else in connection with the matters set out in this announcement. In connection with such matters, Morgan Stanley, its affiliates and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their clients or for providing advice in relation to the contents of this announcement or any other matter referred to herein.

 

Centerview Partners UK LLP ("Centerview Partners") is authorised and regulated by the Financial Conduct Authority. Centerview Partners is acting exclusively for Croda and no one else in connection with the matters referred to in this announcement. Centerview Partners is not and will not be responsible to anyone other than Croda for providing the protections afforded to its clients or for providing advice in connection with the contents of this announcement or any other matter referred to in this announcement. Neither Centerview Partners, nor any of its affiliates, owes or accepts any duty, liability or responsibility whatsoever to any person who is not a client of Centerview Partners in connection with this announcement, any statement contained herein or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISFMMRTMTIJBIT
Date   Source Headline
19th Oct 202311:19 amRNSHolding(s) in Company
19th Oct 202310:34 amRNSDirector/PDMR Shareholding
12th Oct 202311:46 amRNSDirector/PDMR Shareholding
9th Oct 20237:00 amRNSThird Quarter Trading Update
6th Oct 20234:12 pmRNSDirector/PDMR Shareholding
5th Oct 20238:53 amRNSHolding(s) in Company
3rd Oct 20234:03 pmRNSDirector/PDMR Shareholding
27th Sep 20235:17 pmRNSDirector/PDMR Shareholding
26th Sep 202311:38 amRNSDirector/PDMR Shareholding
22nd Sep 20237:00 amRNSDirectorate Change
15th Sep 202311:51 amRNSDirector/PDMR Shareholding
12th Sep 20234:01 pmRNSDirector/PDMR Shareholding
12th Sep 20238:56 amRNSDirector/PDMR Shareholding
11th Aug 20232:26 pmRNSDirector/PDMR Shareholding
1st Aug 20237:13 amRNSDirector Declaration
25th Jul 20237:00 amRNSResults for the six months ended 30 June 2023
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
4th Jul 20238:02 amRNSCroda completes acquisition of Solus Biotech
26th Jun 202310:46 amRNSHolding(s) in Company
13th Jun 20233:55 pmRNSDirector/PDMR Shareholding
12th Jun 20232:06 pmRNSDirector/PDMR Shareholding
9th Jun 20237:00 amRNSTrading update
31st May 20232:47 pmRNSDirector/PDMR Shareholding
26th May 20233:51 pmRNSDirector/PDMR Shareholding
11th May 20234:05 pmRNSDirector/PDMR Shareholding
3rd May 20233:08 pmRNSDirector/PDMR Shareholding
3rd May 20233:00 pmRNSDirector/PDMR Shareholding
2nd May 20232:30 pmRNSDirector/PDMR Shareholding
27th Apr 20239:18 amRNSResult of AGM
24th Apr 20234:49 pmRNSDirector/PDMR Shareholding
12th Apr 20232:00 pmRNSDirector/PDMR Shareholding
28th Mar 20233:51 pmRNSDirector/PDMR Shareholding
28th Mar 20233:50 pmRNSDirector/PDMR Shareholding
28th Mar 20233:47 pmRNSDirector/PDMR Shareholding
28th Mar 20233:46 pmRNSDirector/PDMR Shareholding
28th Mar 20233:44 pmRNSDirector/PDMR Shareholding
28th Mar 20233:42 pmRNSDirector/PDMR Shareholding
28th Mar 20233:41 pmRNSDirector/PDMR Shareholding
28th Mar 20233:41 pmRNSDirector/PDMR Shareholding
27th Mar 20233:52 pmRNSDirector/PDMR Shareholding
27th Mar 20233:48 pmRNSDirector/PDMR Shareholding
24th Mar 202310:57 amRNSDirector/PDMR Shareholding
24th Mar 202310:31 amRNSDirectorate Change
17th Mar 20235:12 pmRNSAnnual Financial Report
17th Mar 20232:30 pmRNSDirector/PDMR Shareholding
17th Mar 202310:53 amRNSDirector/PDMR Shareholding
13th Mar 20232:02 pmRNSDirector/PDMR Shareholding
3rd Mar 202311:57 amRNSDirector/PDMR Shareholding
28th Feb 20239:21 amRNSDirectorate Change
28th Feb 20237:00 amRNSResults for the year ended 31 December 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.